See All Slides - tctmd.com

Slides

Presentation TCT 2015

Myths as to Why SYMPLICITY HTN-3 Failed

Presenter: Ajay J. Kirtane, Felix Mahfoud, Darrel P. Francis

October 11, 2015

Presentation TCT 2015

Nonculprit Lesions in STEMI Patients With Multivessel Disease: Is the Issue Ischemia or Vulnerable Plaque?

Presenter: Thomas Engstroem, Barry D. Rutherford, David Erlinge

October 11, 2015

Presentation TCT 2015

IVUS, OCT, and NIRS Identification of Culprit Lesions in ACS

Presenter: Fernando Alfonso, Akiko Maehara, Jonathan M. Tobis

October 11, 2015

Presentation TCT 2015

The Current Epidemiology and Treatment of Mitral Valvular Regurgitation in the US and EU

Presenter: Patrick T. O'Gara, Allan Schwartz, Jeffrey S. Borer

October 11, 2015

Presentation TCT 2015

Essentials of Quality and Compliance in Research

Presenter: David A. Cox, Thomas D. Stuckey, Kate Dalton

October 11, 2015

Presentation TCT 2015

The Antegrade Approach: Euro CTO Insights

Presenter: J. Aaron Grantham, Masahiko Ochiai, Alfredo R. Galassi

October 11, 2015

Presentation TCT 2015

Pioneers Corner: Reflections on the Impact of TAVR on Aortic Valve Therapy (Now and in the Future) The Cardiac Surgeons Perspective

Presenter: Eberhard Grube, Michael J. Mack

October 11, 2015

Presentation TCT 2015

Should FFR Be Used Routinely in STEMI Patients With Multivessel Disease, and Is It Reliable During the Index and/or Staged Procedures?

Presenter: Thomas Engstroem, Barry D. Rutherford, Colin Berry

October 11, 2015

Presentation TCT 2015

Which NOAC for Which Patient?

Presenter: David R. Holmes Jr., Vivek Y. Reddy, Christopher B. Granger

October 11, 2015

Presentation TCT 2015

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Presenter: Gary M. Ansel, Michael R. Jaff, Ori Ben-Yehuda

October 11, 2015

Advertisement

Slides

Myths as to Why SYMPLICITY HTN-3 Failed

Nonculprit Lesions in STEMI Patients With Multivessel Disease: Is the Issue Ischemia or Vulnerable Plaque?

IVUS, OCT, and NIRS Identification of Culprit Lesions in ACS

The Current Epidemiology and Treatment of Mitral Valvular Regurgitation in the US and EU

Essentials of Quality and Compliance in Research

The Antegrade Approach: Euro CTO Insights

Pioneers Corner: Reflections on the Impact of TAVR on Aortic Valve Therapy (Now and in the Future) The Cardiac Surgeons Perspective

Should FFR Be Used Routinely in STEMI Patients With Multivessel Disease, and Is It Reliable During the Index and/or Staged Procedures?

Which NOAC for Which Patient?

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content